106 related articles for article (PubMed ID: 23799412)
21. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer.
Romee R; Leong JW; Fehniger TA
Scientifica (Cairo); 2014; 2014():205796. PubMed ID: 25054077
[TBL] [Abstract][Full Text] [Related]
22. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.
Boye J; Elter T; Engert A
Ann Oncol; 2003 Apr; 14(4):520-35. PubMed ID: 12649096
[TBL] [Abstract][Full Text] [Related]
23. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Keating GM
Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
[TBL] [Abstract][Full Text] [Related]
24. A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma.
Robertson MJ; Kline J; Struemper H; Koch KM; Bauman JW; Gardner OS; Murray SC; Germaschewski F; Weisenbach J; Jonak Z; Toso JF
J Immunother; 2013; 36(6):331-41. PubMed ID: 23799412
[TBL] [Abstract][Full Text] [Related]
25. A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma.
Robertson MJ; Stamatkin CW; Pelloso D; Weisenbach J; Prasad NK; Safa AR
J Immunother; 2018 Apr; 41(3):151-157. PubMed ID: 29517616
[TBL] [Abstract][Full Text] [Related]
26. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer.
Robertson MJ; Kirkwood JM; Logan TF; Koch KM; Kathman S; Kirby LC; Bell WN; Thurmond LM; Weisenbach J; Dar MM
Clin Cancer Res; 2008 Jun; 14(11):3462-9. PubMed ID: 18519778
[TBL] [Abstract][Full Text] [Related]
27. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801
[TBL] [Abstract][Full Text] [Related]
28. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
29. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
30. Treatment of older patients with mantle-cell lymphoma.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
[TBL] [Abstract][Full Text] [Related]
31. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.
LaCasce AS; Vandergrift JL; Rodriguez MA; Abel GA; Crosby AL; Czuczman MS; Nademanee AP; Blayney DW; Gordon LI; Millenson M; Vanderplas A; Lepisto EM; Zelenetz AD; Niland J; Friedberg JW
Blood; 2012 Mar; 119(9):2093-9. PubMed ID: 22234679
[TBL] [Abstract][Full Text] [Related]
32. Acquired STAT4 deficiency as a consequence of cancer chemotherapy.
Lupov IP; Voiles L; Han L; Schwartz A; De La Rosa M; Oza K; Pelloso D; Sahu RP; Travers JB; Robertson MJ; Chang HC
Blood; 2011 Dec; 118(23):6097-106. PubMed ID: 21998209
[TBL] [Abstract][Full Text] [Related]
33. IL-18 induces PD-1-dependent immunosuppression in cancer.
Terme M; Ullrich E; Aymeric L; Meinhardt K; Desbois M; Delahaye N; Viaud S; Ryffel B; Yagita H; Kaplanski G; Prévost-Blondel A; Kato M; Schultze JL; Tartour E; Kroemer G; Chaput N; Zitvogel L
Cancer Res; 2011 Aug; 71(16):5393-9. PubMed ID: 21724589
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-18: biology and role in the immunotherapy of cancer.
Srivastava S; Salim N; Robertson MJ
Curr Med Chem; 2010; 17(29):3353-7. PubMed ID: 20712569
[TBL] [Abstract][Full Text] [Related]
35. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.
Ferris RL; Jaffee EM; Ferrone S
J Clin Oncol; 2010 Oct; 28(28):4390-9. PubMed ID: 20697078
[TBL] [Abstract][Full Text] [Related]
36. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Cheson BD
J Clin Oncol; 2010 Jul; 28(21):3525-30. PubMed ID: 20458041
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]